Janssen publishes positive safety and efficacy data for single-dose COVID-19 vaccine
The Phase III data show the single-dose vaccine candidate was 66% effective overall in preventing coronavirus, with no serious adverse events in recipients. Phase III trials for the two-dose regimen are ongoing. The UK has secured 30 million doses of the vaccine.
Source:
Department of Health and Social Care
SPS commentary:
Another press release discussing the research notes the interim analysis assessed 468 cases of symptomatic Covid-19 among 44,325 adult volunteers in Argentina, Brazil, Chile, Colombia, Mexico, Peru, South Africa and the US. The vaccine was 66% effective at preventing the combined endpoint of moderate and severe Covid-19 at 28 days post-vaccination, including those infected with an emerging variant. The level of protection varied geographically (e.g. 72% US, 57% South Africa).
The Janssen vaccine is a recombinant vector vaccine that uses a human adenovirus to express the SARS-CoV-2 spike protein.